we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.
Company profile
Ticker
BLUE
Exchange
Website
CEO
Nick Leschly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Genetix Pharmaceuticals Inc
SEC CIK
Corporate docs
Subsidiaries
bluebird bio Securities Corporation • bluebird bio France, SARL • bluebird bio (FR) SAS • bluebird bio Australia Pty Ltd • bluebird bio (Bermuda) Ltd • bluebird bio (UK) Ltd • bluebird bio (Italy) Srl • bluebird bio (Switzerland) GmbH • bluebird bio (Germany) GmbH • Bluebird Bio Greece Single Member, L.L.C. ...
BLUE stock data
Latest filings (excl ownership)
8-K
Other Events
16 Apr 24
8-K
Results of Operations and Financial Condition
26 Mar 24
NT 10-K
Notice of late annual filing
26 Mar 24
8-K
Entry into a Material Definitive Agreement
18 Mar 24
8-K
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
8 Jan 24
8-K
Regulation FD Disclosure
4 Jan 24
424B5
Prospectus supplement for primary offering
20 Dec 23
8-K
Entry into a Material Definitive Agreement
20 Dec 23
424B5
Prospectus supplement for primary offering
18 Dec 23
8-K
Entry into a Material Definitive Agreement
18 Dec 23
Transcripts
BLUE
Earnings call transcript
2023 Q4
26 Mar 24
BLUE
Earnings call transcript
2023 Q3
7 Nov 23
BLUE
Earnings call transcript
2023 Q2
8 Aug 23
BLUE
Earnings call transcript
2022 Q4
29 Mar 23
BLUE
Earnings call transcript
2021 Q2
9 Aug 21
BLUE
Earnings call transcript
2020 Q3
4 Nov 20
BLUE
Earnings call transcript
2020 Q1
11 May 20
BLUE
Earnings call transcript
2018 Q3
2 Nov 18
BLUE
Earnings call transcript
2017 Q3
1 Nov 17
Latest ownership filings
SC 13G/A
STATE STREET CORP
10 Apr 24
4
Richard A Colvin
5 Mar 24
4
Joseph Vittiglio
5 Mar 24
4
Andrew Obenshain
5 Mar 24
4
Christopher Krawtschuk
5 Mar 24
4
Thomas J Klima
5 Mar 24
SC 13G/A
PFM Health Sciences, LP
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
Alyeska Investment Group, L.P.
14 Feb 24
SC 13G
Granahan Investment Management, LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 218.37 mm | 218.37 mm | 218.37 mm | 218.37 mm | 218.37 mm | 218.37 mm |
Cash burn (monthly) | (no burn) | (no burn) | 28.24 mm | 9.70 mm | 20.62 mm | 23.12 mm |
Cash used (since last report) | n/a | n/a | 187.89 mm | 64.55 mm | 137.14 mm | 153.83 mm |
Cash remaining | n/a | n/a | 30.48 mm | 153.82 mm | 81.23 mm | 64.54 mm |
Runway (months of cash) | n/a | n/a | 1.1 | 15.9 | 3.9 | 2.8 |
Institutional ownership, Q3 2023
90.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 166 |
Opened positions | 16 |
Closed positions | 22 |
Increased positions | 55 |
Reduced positions | 47 |
13F shares | Current |
---|---|
Total value | 267.77 bn |
Total shares | 98.80 mm |
Total puts | 806.40 k |
Total calls | 861.50 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
STT State Street | 12.67 mm | $38.50 bn |
BLK Blackrock | 8.83 mm | $26.84 bn |
Partner Fund Management | 6.04 mm | $18.36 bn |
Vanguard | 5.62 mm | $17.08 bn |
Growth Fund Of America | 5.20 mm | $515.44 mm |
Pictet Asset Management Holding | 5.15 mm | $15.65 bn |
Granahan Investment Management | 5.14 mm | $15.62 bn |
Tang Capital Partners | 4.64 mm | $0.00 |
Tang Capital Management | 4.28 mm | $13.02 bn |
Woodline Partners | 2.73 mm | $8.30 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Andrew Obenshain | Common Stock | Sell | Dispose S | No | No | 1.5276 | 6,095 | 9.31 k | 279,998 |
4 Mar 24 | Thomas J Klima | Common Stock | Sell | Dispose S | No | No | 1.5276 | 4,573 | 6.99 k | 124,840 |
1 Mar 24 | Richard A Colvin | Common Stock | Sell | Dispose S | No | No | 1.5276 | 6,770 | 10.34 k | 118,368 |
1 Mar 24 | Richard A Colvin | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 199,000 | 310.44 k | 199,000 |
1 Mar 24 | Joseph Vittiglio | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 199,000 | 310.44 k | 199,000 |
1 Mar 24 | Andrew Obenshain | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 650,000 | 1.01 mm | 650,000 |
1 Mar 24 | Christopher Krawtschuk | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 199,000 | 310.44 k | 199,000 |
1 Mar 24 | Thomas J Klima | Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 199,000 | 310.44 k | 199,000 |
News
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
27 Mar 24
RBC Capital Reiterates Sector Perform on bluebird bio, Maintains $6 Price Target
27 Mar 24
Wells Fargo Maintains Equal-Weight on bluebird bio, Lowers Price Target to $3
27 Mar 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
26 Mar 24
bluebird bio Q4 Sales $7.80M May Not Be Comparable To $16.68M Estimate
26 Mar 24
Press releases
ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
18 Apr 24
Investors who lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class Action - BLUE
18 Apr 24
DEADLINE ALERT for EVLV, BLUE, and LUNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
18 Apr 24
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
17 Apr 24
BLUE Lawsuit: Robbins LLP Reminds Investors of bluebird bio, Inc. of Pending Lead Plaintiff Deadline
17 Apr 24